Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891146 | 0.91 | ESR1 (0.72) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL891147 | 0.88 | ESR1 (0.64) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL4578515 | 0.87 | TSHR (0.52) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL20483494 | 0.83 | ESR1 (0.79) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL4578281 | 0.82 | ACP3 (0.47) | TSHRTP53ESR1ESR2SLC6A3 | |
| SCHEMBL4914536 | 0.81 | TSHR (0.46) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL19260228 | 0.81 | TSHR (0.59) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL4216010 | 0.79 | TSHR (0.57) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL21473833 | 0.79 | TSHR (0.62) | TSHRTP53ESR1ESR2LMNA | |
| SCHEMBL8462360 | 0.79 | TSHR (0.62) | TSHRTP53ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101656-A1 | IN SITU GELLING DRUG DELIVERY SYSTEM | CONTROL DELIVERY SYSTEMS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8143437-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090239950-A1 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7560483-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050239725-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6927036-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XERO PORT, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1485082-A1 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF | Xenoport, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077902-A1 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | ARBOR PHARMACEUTICALS, LLC | 2003-09-11 | — | — | US | disclosed |
| CN-1143907-A | Pharmaceutical composition | NORSK HYDRO AS (NO) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101656-A1 | IN SITU GELLING DRUG DELIVERY SYSTEM | ABCB11, MMP1, IDE | TSHR 3405/4885TP53 2486/4885ESR1 166/4885 |
| US-20090239950-A1 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF | AADAC, UGT1A1, ABHD5 | TSHR 4384/4885TP53 3112/4885ESR1 2521/4885 |
| US-20030171303-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | AADAC, UGT1A1, AGPAT5 | TSHR 4306/4885TP53 3168/4885ESR1 2648/4885 |
| US-20050239725-A1 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | AADAC, UGT1A1, ABHD5 | TSHR 4384/4885TP53 3112/4885ESR1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.